Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2016 Jan 29

PMID 26817900

Citations 41

Authors

Xiaotao Yin

Yi Xiao

Fanglong Li

Siyong Qi

Zhaoyang Yin

Jiangping Gao

Affiliations

Soon will be listed here.

Abstract

Inflammation is increasingly reported to be associated with the prognosis of patients with cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa) remains inconsistent. Therefore, we conducted this systematic review and meta-analysis to obtain a more reliable assessment of prognostic significance of NLR in PCa.A comprehensive literature research regarding the association of NLR and prognosis of PCa was performed through PubMed, Embase, Cochrane Central, and Web of Science. The hazard ratios (HRs) and its 95% confidence intervals (CIs) for overall survival (OS), progression-free survival, or recurrence-free survival were extracted and pooled using fix-effects model or random-effects model.A total of 14 studies that met our criterion were included in this meta-analysis. Our pooled results demonstrated that elevated NLR was not significantly associated with the poor OS (HR = 1.45; 95% CI 0.77-2.71; P = 0.248) or recurrence-free survival (HR = 1.34; 95% CI 0.89-2.02; P = 0.155) of patients with localized PCa. Although elevated NLR predicted poorer OS (HR = 1.57; 95% CI 1.41-1.74; P < 0.001) and progression-free survival (HR = 1.97; 95% CI 1.28-3.04; P = 0.002) of patients with metastatic castration resistant prostate cancer (mCRPC).Elevated NLR is a strong indicator of poorer prognosis of patients with mCRPC, whereas the NLR is not significantly associated with prognosis of patients with localized PCa. Therefore, NLR could be used in patients with mCRPC for risk stratification and decision making of individual treatment.

Citing Articles

Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.

Steffens F, Wessels F, Hetjens S, Carl N, Nitschke K, Uysal D Int Urol Nephrol. 2025; .

PMID: 39871032 DOI: 10.1007/s11255-025-04389-2.

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis.

Zhang Y, Zhou X, Xu R, Luo G, Wang X BMC Urol. 2025; 25(1):17.

PMID: 39865253 PMC: 11770999. DOI: 10.1186/s12894-024-01685-4.

Associations of HALP score with serum prostate-specific antigen and mortality in middle-aged and elderly individuals without prostate cancer.

Chen Z, Zhang Y, Dan M, Hong X, Chen S, Zhong X Front Oncol. 2024; 14:1419310.

PMID: 39372874 PMC: 11449680. DOI: 10.3389/fonc.2024.1419310.

Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.

Sahin E, Kefeli U, Zorlu S, Seyyar M, Ozkorkmaz Akdag M, Sanci P Medicine (Baltimore). 2023; 102(47):e35843.

PMID: 38013293 PMC: 10681561. DOI: 10.1097/MD.0000000000035843.

Investigating Nutritional and Inflammatory Status as Predictive Biomarkers in Oligoreccurent Prostate Cancer-A RADIOSA Trial Preliminary Analysis.

Zaffaroni M, Vincini M, Corrao G, Lorubbio C, Repetti I, Mastroleo F Nutrients. 2023; 15(21).

PMID: 37960236 PMC: 10647217. DOI: 10.3390/nu15214583.

References

Hernandez D, Nielsen M, Han M, Partin A . Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology. 2007; 70(5):931-5. DOI: 10.1016/j.urology.2007.08.055. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Nind A, Nairn R, Rolland J, Guli E, Hughes E . Lymphocyte anergy in patients with carcinoma. Br J Cancer. 1973; 28(2):108-17. PMC: 2008880. DOI: 10.1038/bjc.1973.128. View

Li M, Liu X, Zhang X, Zhang J, Wang W, Zhu Y . Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2013; 134(10):2403-13. DOI: 10.1002/ijc.28536. View

Petrie H, Klassen L, Kay H . Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985; 134(1):230-4. View

Lorente D, Mateo J, Templeton A, Zafeiriou Z, Bianchini D, Ferraldeschi R . Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2014; 26(4):750-755. DOI: 10.1093/annonc/mdu587. View

Hofman P . Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol. 2010; 16(46):5790-800. PMC: 3001969. DOI: 10.3748/wjg.v16.i46.5790. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S . Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010; 120(4):1151-64. PMC: 2846036. DOI: 10.1172/JCI37223. View

10.

Templeton A, Pezaro C, Omlin A, McNamara M, Leibowitz-Amit R, Vera-Badillo F . Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014; 120(21):3346-52. DOI: 10.1002/cncr.28890. View

11.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

12.

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

13.

Yao A, Sejima T, Iwamoto H, Masago T, Morizane S, Honda M . High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015; 22(9):827-33. DOI: 10.1111/iju.12839. View

14.

Gooden M, de Bock G, Leffers N, Daemen T, Nijman H . The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105(1):93-103. PMC: 3137407. DOI: 10.1038/bjc.2011.189. View

15.

Sonpavde G, Pond G, Armstrong A, Clarke S, Vardy J, Templeton A . Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014; 12(5):317-24. DOI: 10.1016/j.clgc.2014.03.005. View

16.

Langsenlehner T, Thurner E, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Gerger A . Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol. 2015; 33(11):1661-7. DOI: 10.1007/s00345-015-1494-7. View

17.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

18.

Nuhn P, Vaghasia A, Goyal J, Zhou X, Carducci M, Eisenberger M . Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2014; 114(6b):E11-E17. PMC: 4004702. DOI: 10.1111/bju.12531. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

20.

Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, ZAMORA E . Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012; 14(11):864-9. DOI: 10.1007/s12094-012-0872-5. View